Dyne Therapeutics (NASDAQ:DYN) vs. Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Head-To-Head Comparison

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.

Volatility and Risk

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Institutional & Insider Ownership

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Calliditas Therapeutics AB (publ) and Dyne Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-40.19%	-160.87%	-30.64%
Dyne Therapeutics	N/A	-110.92%	-90.00%

Valuation & Earnings

This table compares Calliditas Therapeutics AB (publ) and Dyne Therapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60 billion	0.75	-$43.96 million	($1.85)	-21.90
Dyne Therapeutics	N/A	N/A	-$235.94 million	($3.97)	-11.09

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Dyne Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Calliditas Therapeutics AB (publ) and Dyne Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0	5	0	0	2.00
Dyne Therapeutics	0	0	9	1	3.10

Calliditas Therapeutics AB (publ) presently has a consensus target price of $39.25, suggesting a potential downside of 3.11%. Dyne Therapeutics has a consensus target price of $50.60, suggesting a potential upside of 14.92%. Given Dyne Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Summary

Dyne Therapeutics beats Calliditas Therapeutics AB (publ) on 9 of the 14 factors compared between the two stocks.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.